3/14
09:31 am
cnta
Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start [Yahoo! Finance]
Medium
Report
Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start [Yahoo! Finance]
3/8
03:27 pm
cnta
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference [Yahoo! Finance]
Low
Report
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference [Yahoo! Finance]
2/26
02:10 pm
cnta
Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]
Low
Report
Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]
2/25
06:24 am
cnta
Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".
2/24
08:00 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.
2/3
08:00 am
cnta
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Neutral
Report
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
1/29
10:35 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $33.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $33.00 to $38.00. They now have a "buy" rating on the stock.
1/16
02:04 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/15
06:42 am
cnta
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting [Yahoo! Finance]
Low
Report
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting [Yahoo! Finance]
1/14
05:00 pm
cnta
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Low
Report
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
1/14
01:05 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/12
10:33 am
cnta
Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis [Yahoo! Finance]
Neutral
Report
Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis [Yahoo! Finance]
1/8
12:20 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $30.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $30.00 to $33.00. They now have a "buy" rating on the stock.
1/8
09:47 am
cnta
Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal [Yahoo! Finance]
Low
Report
Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal [Yahoo! Finance]
1/2
08:02 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
Medium
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.